Musi wa22 Ndira, 2025, "Nature Medicine" yakaburitsa zvakabuda muAkeso yakagadzira yega PD-1/CTLA-4 bispecific antibody cadonilimab pamwe chete neoxaliplatin necapecitabine kuti irapwe mushonga wekutanga wekurapa chirwere chemudumbu (G/GEJ) adenocarcinoma (G/GEJ) chisina kubviswa mumuviri kana kuti chakapararira mumuviri muchikamu chechitatu chekiriniki (COMPASSION-15/AK104-302).Zvakabuda muchidzidzo cheCOMPASSION-15 zvakambotaurwa nemuromo pamusangano wegore negore weAmerican Association for Cancer Research (AACR) wegore ra2024.
Ichi chaive chidzidzo chechikamu chechitatu chakaitwa nemaitiro asina kujeka, chisina kubatwa, chakaitwa nemaoko maviri, uye chakaitwa neplacebo. Varwere vakakodzera vaive vakuru vane G/GEJ adenocarcinoma isina kurapwa, isingarapwe, yakakwira munharaunda kana kuti yakapararira. Varwere vakarapwa nemaitiro asina kurongeka 1:1 kuti vagamuchire cadonilimab (10 mg kg−1 mavhiki matatu ega ega) kana placebo pamwe nechemotherapy (mavhiki matatu ega ega). Mugumo mukuru waive wekurarama kwese (OS) muvanhu vaida kurapwa (one-sided significance level, P = 0.025). Magumo echipiri aisanganisira OS muvarwere vane PD-L1 combined positive score ≥5, progressive-free survival, objective response rate, nguva yekupindura uye kuchengetedzeka. Kubva musi wa18 Nyamavhuvhu 2023, varwere 610 vanobva kunzvimbo dzekudzidza 75 vakarapwa nemaitiro asina kurongeka kuti vapihwe cadonilimab (n = 305) kana placebo (n = 305). Nekutevera kwepakati kwemwedzi 18.7, boka re cadonilimab raive nepakati peOS (mwedzi 14.1 uchienzaniswa nemwedzi 11.1; hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.54–0.81; P < 0.001) kupfuura boka re placebo. Mugumo wekutanga wakawanikwa. Kurarama kwepakati pasina progression kwaive kwemwedzi 7.0 uchienzaniswa nemwedzi 5.3 (HR 0.53, 95% CI 0.44–0.65). Pakati peOS muvarwere vane PD-L1 yakabatana positive score ≥5 yaive mwedzi 15.3 uchienzaniswa nemwedzi 10.9 (HR 0.58, 95% CI 0.41–0.82). Chiyero chekupindura chaive 65.2% uchienzaniswa ne48.9% nepakati penguva yekupindura kwemwedzi 8.8 uchienzaniswa nemwedzi 4.4. Zviitiko zvakaipa zvine chekuita nekurapwa zveGiredhi ≥3 zvakaitika mu65.9% yeboka re cadonilimab uye 53.6% yeboka re placebo, uye zvakanyanya kuwanda kwaive kudzikira kwehuwandu hwemaplatelet, kudzikira kwehuwandu hwema neutrophil uye anemia. Zviitiko zvakawanda zvakashata zvine chekuita nekudzivirira muviri zvaive zveGiredhi 1 kana 2. Hapana zviratidzo zvitsva zvekuchengetedza zvakaonekwa. Cadonilimab pamwe ne chemotherapy zvakavandudza zvakanyanya OS nekuchengetedza kunogoneka muvarwere vane G/GEJ adenocarcinoma yepamusoro.
Jekiseni reCadonilimab mushonga mutsva, wekutanga mukirasi yePD-1/CTLA-4 bi-specific immunotherapy wakagadzirwa mumba. Musi wa29 Chikumi, 2022, Cadonilimab yakapihwa mvumo yekushambadzira neNMPA yeChina yekurapa varwere vekenza yemuromo wechibereko vakadzokera shure kana kuti vakapararira (R/M CC) avo vakaenderera mberi mushure me chemotherapy yakagadzirwa neplatinum. MunaGunyana 2024, chiratidzo chitsva checadonilimab chabvumidzwa kurapwa kwekutanga kwevarwere vane chirwere chemudumbu chisingarapiki kana chakapararira (G/GEJ) adenocarcinoma, pamwe chete nefluoropyrimidine uye chemotherapy yakagadzirwa neplatinum. Parizvino, kushandiswa kwemishonga mitsva yeCadonilimab pamwe chete ne chemotherapy yakagadzirwa neplatinum, ine kana isina bevacizumab, yekurapa kwekutanga kwekenza yemuromo wechibereko inoramba iripo, inodzokorora, kana yakapararira yakagamuchirwa neCDE. Pamusoro pezvo, zvidzidzo zvakasiyana-siyana zvekiriniki, kusanganisira bvunzo yechikamu chechitatu chekurapa kweadjuvant muvarwere vane njodzi huru yekudzoka mushure mekubviswa kwehepatocellular carcinoma, zviri kuitwa zvinobudirira.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Mareferensi
https://www.nature.com/articles/s41591-024-03450-4
Nguva yekutumira: Kukadzi-21-2025